This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

CVA (acute, aspirin in)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

A combined analysis of the results of the International Stroke Trial and the Chinese Acute Stroke Trial suggested that early death, recurrent stroke or late death can be prevented in 1 patient with acute stroke by giving aspirin to 100 patients with acute stroke.

NICE advise that all people presenting with acute stroke who have had a diagnosis of primary intracerebral haemorrhage excluded by brain imaging should, as soon as possible but certainly within 24 hours, be treated with aspirin:

  • aspirin 300 mg orally if they are not dysphagic or
  • aspirin 300 mg rectally or by enteral tube if they are dysphagic

Thereafter, aspirin 300 mg should be continued until 2 weeks after the onset of stroke symptoms, at which time definitive long-term antithrombotic treatment should be initiated.

Patients being discharged before 2 weeks can be started on long-term treatment earlier.

If there is a history of dyspepsia associated with aspirin then combination therapy with a proton pump inhibitor is recommended.

If the patient is allergic or intolerant of aspirin then an alternative antiplatelet agent, such as clopidogrel or dipyridamole, should be given.

Anticoagulation, with for example heparin, should is not routinely indicated for the treatment of acute stroke.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.